I don’t like podcasts, they have too low information density.
So, let me quote from Wiki on everolymus which is the same thing as the RAD001 referenced in your link (the paper is produced by Novartis, by the way):
A trial using 10 mg/day in patients with NETs of GI or lung origin reported “Everolimus was discontinued for adverse reactions in 29% of patients and dose reduction or delay was required in 70% of everolimus-treated patients. Serious adverse reactions occurred in 42% of everolimus-treated patients and included 3 fatal events (cardiac failure, respiratory failure, and septic shock). The most common adverse reactions (incidence greater than or equal to 30%) were stomatitis, infections, diarrhea, peripheral edema, fatigue and rash. The most common laboratory abnormalities (incidence greater than or equal to 50%) were anemia, hypercholesterolemia, lymphopenia, elevated aspartate transaminase (AST) and fasting hyperglycemia.”.[7]
Does that answer your question of why self-experimentation with mTOR inhibitors is not popular?
Link..?
This is the same study that is cited in the highly informative podcast that I posted earlier to the open thread.
I don’t like podcasts, they have too low information density.
So, let me quote from Wiki on everolymus which is the same thing as the RAD001 referenced in your link (the paper is produced by Novartis, by the way):
Does that answer your question of why self-experimentation with mTOR inhibitors is not popular?
My expectations of self-experimenters to put themselves in potential harm is overestimated.